T. Rowe Price Investment Management, Inc. Erasca, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 20,332,161 shares of ERAS stock, worth $31.7 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
20,332,161
Previous 17,292,164
17.58%
Holding current value
$31.7 Million
Previous $23.7 Million
8.99%
% of portfolio
0.02%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding ERAS
# of Institutions
149Shares Held
217MCall Options Held
258KPut Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$35.5 Million1.52% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$27.9 Million4.49% of portfolio
-
Logos Global Management LP San Francisco, CA15MShares$23.4 Million2.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$22.6 Million0.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$19.8 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $191M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...